DefiniGEN provides human cells to the life science and drug discovery sectors for use in lead optimization and toxicity programmes. DefiniGEN’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.
